Skip to main content
Erschienen in: Drug Safety 1/2001

01.01.2001 | Current Opinion

The Role of the Clinical Pharmacologist in the Management of Adverse Drug Reactions

verfasst von: Dr Nicholas Moore

Erschienen in: Drug Safety | Ausgabe 1/2001

Einloggen, um Zugang zu erhalten

Abstract

The classical definition of clinical pharmacology is the study or the knowledge of the effects of drugs in humans. The activities of a clinical pharmacologist can vary from country to country, usually ranging from involvement in clinical trials, especially fundamental pharmacodynamic studies, to studies of pharmacokinetics and drug metabolism, to pharmacogenetics. Most clinical pharmacologists outside industry are in hospitals or university hospitals and research centres. In addition to research, this implies teaching of clinical pharmacology, and interacting with other medical staff: in the field of research, giving advice on clinical trials methodology and often managing a therapeutic drug monitoring centre. Some clinical pharmacologists have clinical departments with beds or consulting offices.
Can there be another role for the clinical pharmacologist that would increase his or her usefulness for the medical community? Adverse drug reactions (ADRs) are remarkably complex events, related to drug effects, patient characteristics (background diseases, genetics), and drug/disease interactions.
Evaluation of ADRs requires understanding of drug mechanisms and interactions, and of disease diagnostics, especially in the discussion of alternative diagnoses. This implies expertise as a pharmacologist and a clinician. In addition, because not all adverse reactions or interactions are in the Summary of Product Characteristics, and because problems arise long before they report in the literature, it is necessary for the clinical pharmacologist to have knowledge of ongoing regulatory processes, in addition to having access to the published literature. Helping clinicians cope with individual patient problems will also improve the clinical pharmacologist’s integration into the healthcare process.
Literatur
1.
Zurück zum Zitat Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22(2): 161–8PubMedCrossRef Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22(2): 161–8PubMedCrossRef
2.
Zurück zum Zitat Moore N, Lecointre D, Noblet C, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45(3): 301–8PubMedCrossRef Moore N, Lecointre D, Noblet C, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45(3): 301–8PubMedCrossRef
3.
Zurück zum Zitat Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85(1-2): 169–82PubMedCrossRef Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85(1-2): 169–82PubMedCrossRef
4.
Zurück zum Zitat White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics 1999; 15(5): 445–58PubMedCrossRef White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics 1999; 15(5): 445–58PubMedCrossRef
5.
6.
Zurück zum Zitat Rawlins MD. Spontaneous reporting of adverse drug reactions. I: the data. Br J Clin Pharmacol 1988; 26(1): 1–5PubMedCrossRef Rawlins MD. Spontaneous reporting of adverse drug reactions. I: the data. Br J Clin Pharmacol 1988; 26(1): 1–5PubMedCrossRef
7.
Zurück zum Zitat Rawlins MD. Spontaneous reporting of adverse drug reactions. II: uses. Br J Clin Pharmacol 1988; 26(1): 7–11PubMedCrossRef Rawlins MD. Spontaneous reporting of adverse drug reactions. II: uses. Br J Clin Pharmacol 1988; 26(1): 7–11PubMedCrossRef
8.
Zurück zum Zitat Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 2000; 320(7241): 1036PubMedCrossRef Pouyanne P, Haramburu F, Imbs JL, et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 2000; 320(7241): 1036PubMedCrossRef
9.
Zurück zum Zitat Imbs JL, Pouyanne P, Haramburu F, et al. Iatrogenic medication: estimation of its prevalence in French public hospitals. Regional Centers of Pharmacovigilance. Therapie 1999; 54(1): 21–7PubMed Imbs JL, Pouyanne P, Haramburu F, et al. Iatrogenic medication: estimation of its prevalence in French public hospitals. Regional Centers of Pharmacovigilance. Therapie 1999; 54(1): 21–7PubMed
10.
Zurück zum Zitat Salom IL, Davis K. Prescribing for older patients: how to avoid toxic drug reactions. Geriatrics 1995; 50(10): 37–40PubMed Salom IL, Davis K. Prescribing for older patients: how to avoid toxic drug reactions. Geriatrics 1995; 50(10): 37–40PubMed
11.
Zurück zum Zitat Dartnell JG, Anderson RP, Chohan V, et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 1996; 164(11): 659–62PubMed Dartnell JG, Anderson RP, Chohan V, et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 1996; 164(11): 659–62PubMed
12.
Zurück zum Zitat Moore N, Verschuren X, Montout C, et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. Therapie 2000; 55(1): 133–6PubMed Moore N, Verschuren X, Montout C, et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. Therapie 2000; 55(1): 133–6PubMed
13.
Zurück zum Zitat Capella D, Laporte JR, Vidal X, et al. European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study. Eur J Clin Pharmacol 1998; 53(5): 299–302PubMedCrossRef Capella D, Laporte JR, Vidal X, et al. European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study. Eur J Clin Pharmacol 1998; 53(5): 299–302PubMedCrossRef
14.
Zurück zum Zitat CAST investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321 (6): 406–12 CAST investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321 (6): 406–12
15.
Zurück zum Zitat Council for International Organizations of Medical Sciences. Benefit-risk balance for marketed drugs. Calculating safety signals. Geneva: CIOMS, 1998 Council for International Organizations of Medical Sciences. Benefit-risk balance for marketed drugs. Calculating safety signals. Geneva: CIOMS, 1998
16.
17.
Zurück zum Zitat Backstrom M, Dahlqvist R, Mjorndal T, et al. A regional center for reporting adverse drug reactions in Umea. Prompt handling results in quick feedback. Lakartidningen 1995; 92(3): 148–50PubMed Backstrom M, Dahlqvist R, Mjorndal T, et al. A regional center for reporting adverse drug reactions in Umea. Prompt handling results in quick feedback. Lakartidningen 1995; 92(3): 148–50PubMed
18.
Zurück zum Zitat Blayac JP, Haramburu F, Lerebours S, et al. Drug information and prescription guidance: role of regional centers of pharmacovigilance. Presse Med 2000; 29(2): 115–8PubMed Blayac JP, Haramburu F, Lerebours S, et al. Drug information and prescription guidance: role of regional centers of pharmacovigilance. Presse Med 2000; 29(2): 115–8PubMed
19.
Zurück zum Zitat Mariani L. Pharmacovigilance: education and continuing updating. The role of university institutes. Clin Ter 1998; 149(3): 219–25PubMed Mariani L. Pharmacovigilance: education and continuing updating. The role of university institutes. Clin Ter 1998; 149(3): 219–25PubMed
20.
Zurück zum Zitat Schwarz UI, Stoelben S, Ebert U, et al. Regional drug information service. Int J Clin Pharmacol Ther 1999; 37(6): 263–8PubMed Schwarz UI, Stoelben S, Ebert U, et al. Regional drug information service. Int J Clin Pharmacol Ther 1999; 37(6): 263–8PubMed
21.
Zurück zum Zitat Troger U, Meyer FP. The regional drug-therapy consultation service centre — a conception that has been serving patients and physicians alike for 30 years in Magdeburg (Germany). Eur J Clin Pharmacol 2000; 55(10): 707–11PubMedCrossRef Troger U, Meyer FP. The regional drug-therapy consultation service centre — a conception that has been serving patients and physicians alike for 30 years in Magdeburg (Germany). Eur J Clin Pharmacol 2000; 55(10): 707–11PubMedCrossRef
22.
Zurück zum Zitat Hoffmann A, Hippius M, Sicker T. Adverse drug reaction monitoring in Jena—experiences of a regionalized pharmacovigilance centre. Exp Toxicol Pathol 1998; 50: 453–7PubMedCrossRef Hoffmann A, Hippius M, Sicker T. Adverse drug reaction monitoring in Jena—experiences of a regionalized pharmacovigilance centre. Exp Toxicol Pathol 1998; 50: 453–7PubMedCrossRef
23.
Zurück zum Zitat Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; II(8463): 1056–8CrossRef Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; II(8463): 1056–8CrossRef
24.
Zurück zum Zitat Laporte JR, Capella D. The Spanish drug surveillance system. Med Clin (Barc) 1994; 103(9): 335–6 Laporte JR, Capella D. The Spanish drug surveillance system. Med Clin (Barc) 1994; 103(9): 335–6
25.
Zurück zum Zitat Wiholm BE, Olsson S, Moore N, et al. Spontaneous reporting systems outside the United States. In: Strom B, editor. Pharmacoepidemiology. 3rd ed. Chichester: John Wiley & Sons, 2000: 139–155 Wiholm BE, Olsson S, Moore N, et al. Spontaneous reporting systems outside the United States. In: Strom B, editor. Pharmacoepidemiology. 3rd ed. Chichester: John Wiley & Sons, 2000: 139–155
Metadaten
Titel
The Role of the Clinical Pharmacologist in the Management of Adverse Drug Reactions
verfasst von
Dr Nicholas Moore
Publikationsdatum
01.01.2001
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 1/2001
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200124010-00001

Weitere Artikel der Ausgabe 1/2001

Drug Safety 1/2001 Zur Ausgabe